Drug intelligence / Profile preview

ITOP5

Development stage: Preclinical
Lead developer: Infinitopes
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular

Overview

ITOP5 is a preclinical-stage, off-the-shelf peptide-based cancer vaccine being developed by Infinitopes. It is designed to target specific tumor-associated antigens to stimulate a T-cell-mediated immune response against cancer cells. As part of Infinitopes' pipeline, ITOP5 is currently being evaluated for an undisclosed cancer indication (referred to as indication #5). The vaccine utilizes the company's proprietary antigen discovery platform to identify high-confidence targets that are shared across patient populations, enabling an off-the-shelf therapeutic approach.

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on ITOP5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITOP5.

Explore the full profile